Advertisement for orthosearch.org.uk
Orthopaedic Proceedings Logo

Receive monthly Table of Contents alerts from Orthopaedic Proceedings

Comprehensive article alerts can be set up and managed through your account settings

View my account settings

Visit Orthopaedic Proceedings at:

Loading...

Loading...

Full Access

General Orthopaedics

THROMBOPROPHYLAXIS IN TOTAL HIP AND KNEE REPLACEMENTS: LOW MOLECULAR WEIGHT HEPARIN AND MINIWARFARIN - A NOVEL PROTOCOL

British Orthopaedic Specialists Association (BOSA)



Abstract

Aim

Thromboprophylaxis in total hip replacement (THR) and total knee replacement (TKR) remains controversial, conspicuous by absence of consensus. Because of protracted and variable mobilisation, there is an extended risk of Venous Thromboembolism (VTE). We hypothesised that a combination of low molecular weight heparin and miniwarfarin would minimise the initial and extended risk. Therefore we evolved a protocol of enoxaparin sodium 40 mgs for 5 days starting preoperatively and miniwarfarin 1-2mg for 6 weeks following surgery. We undertook a retrospective study of total hip and knee replacements in a District General Hospital between January 2000 and December 2005 to determine the effectiveness of the protocol.

Methods

We analysed the incidence of symptomatic VTE in 1307 patients, of who 681 underwent THR and 626 TKR. We evaluated the incidence of symptomatic DVT and PE between 0-6 weeks, 6 weeks-3months and 3-6 months following surgery.

Results

Total incidence of VTE in the study group as a whole including both total hip and knee arthroplasty in 6 months following surgery was 29/1307 (2.22%), after THR 12/681 (1.76%) and after TKR 17/626 (2.72%). VTE at 6 weeks following TKR was 12/626 (1.92%) and THR 4/681(0.59%); between 6 weeks-3 months following TKR 1/626 (0.16%) and THR 6/681 (0.88%); between 3- 6 months 4/626 (0.64%) following TKR and 2/681 (0.29%) after THR. DVT following TKR was 12/626 (1.92%) at 6 months and following THR 7/681 (1.03%). PE at 6 months after TKR was 5/626 (0.80%) and THR 5/681(0.73%) with no attributable mortality.

Conclusions

The incidence of VTE using our thromboprophylaxis protocol - low molecular weight heparin (LMWH) and very low dose warfarin - in THR and TKR not only compares favourably with other modes of thrombo-prophylaxis in literature, but also is cheap and cost effective.